Verition Fund Management LLC boosted its stake in Becton Dickinson and Co (NYSE:BDX) by 498.4% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 9,490 shares of the medical instruments supplier’s stock after purchasing an additional 7,904 shares during the period. Verition Fund Management LLC’s holdings in Becton Dickinson and were worth $2,031,000 at the end of the most recent quarter.
Other institutional investors also recently bought and sold shares of the company. Clark Capital Management Group Inc. purchased a new stake in shares of Becton Dickinson and during the 4th quarter worth $980,000. LPL Financial LLC lifted its position in Becton Dickinson and by 16.8% in the fourth quarter. LPL Financial LLC now owns 26,503 shares of the medical instruments supplier’s stock valued at $5,673,000 after acquiring an additional 3,815 shares during the last quarter. Covington Capital Management lifted its position in Becton Dickinson and by 1.6% in the fourth quarter. Covington Capital Management now owns 16,214 shares of the medical instruments supplier’s stock valued at $3,471,000 after acquiring an additional 255 shares during the last quarter. STA Wealth Management LLC purchased a new stake in shares of Becton Dickinson and in the fourth quarter valued at about $450,000. Finally, Sciencast Management LP acquired a new position in shares of Becton Dickinson and during the fourth quarter worth about $201,000. Hedge funds and other institutional investors own 83.40% of the company’s stock.
A number of research analysts have recently issued reports on the stock. Piper Jaffray reiterated an “overweight” rating and set a $260.00 price target (up from $223.00) on shares of Becton Dickinson and in a research note on Tuesday, February 6th. BMO Capital Markets started coverage on shares of Becton Dickinson and in a research report on Monday, March 5th. They set a “market perform” rating and a $249.00 target price on the stock. Zacks Investment Research raised shares of Becton Dickinson and from a “hold” rating to a “buy” rating and set a $240.00 price target on the stock in a report on Wednesday, January 3rd. Evercore ISI assumed coverage on shares of Becton Dickinson and in a report on Wednesday, January 3rd. They issued an “outperform” rating and a $245.00 price target on the stock. Finally, Argus upped their price objective on shares of Becton Dickinson and to $235.00 and gave the company a “buy” rating in a research note on Thursday, December 14th. They noted that the move was a valuation call. Six equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. Becton Dickinson and currently has an average rating of “Buy” and a consensus target price of $240.53.
BDX traded down $4.63 during trading hours on Friday, reaching $215.50. 1,320,605 shares of the stock traded hands, compared to its average volume of 1,153,007. The firm has a market cap of $58,607.96, a price-to-earnings ratio of 22.73, a PEG ratio of 1.60 and a beta of 1.15. Becton Dickinson and Co has a fifty-two week low of $175.66 and a fifty-two week high of $248.39. The company has a current ratio of 1.54, a quick ratio of 0.93 and a debt-to-equity ratio of 1.04.
Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.41 by $0.07. The company had revenue of $3.08 billion during the quarter, compared to analyst estimates of $3.05 billion. Becton Dickinson and had a net margin of 2.71% and a return on equity of 16.19%. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period last year, the business earned $2.33 EPS. analysts forecast that Becton Dickinson and Co will post 10.95 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, March 30th. Shareholders of record on Friday, March 9th were issued a dividend of $0.75 per share. This represents a $3.00 annualized dividend and a yield of 1.39%. The ex-dividend date of this dividend was Thursday, March 8th. Becton Dickinson and’s dividend payout ratio is currently 31.65%.
In other news, EVP Thomas E. Polen, Jr. sold 1,877 shares of the firm’s stock in a transaction dated Tuesday, March 13th. The shares were sold at an average price of $227.00, for a total value of $426,079.00. Following the transaction, the executive vice president now directly owns 15,387 shares in the company, valued at approximately $3,492,849. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Timothy M. Ring sold 269,661 shares of the firm’s stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $217.82, for a total transaction of $58,737,559.02. Following the completion of the transaction, the director now owns 295,753 shares in the company, valued at $64,420,918.46. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 281,108 shares of company stock worth $61,321,396. Insiders own 1.00% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Becton Dickinson and Co (NYSE:BDX) Shares Bought by Verition Fund Management LLC” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://www.dispatchtribunal.com/2018/04/07/verition-fund-management-llc-buys-7904-shares-of-becton-dickinson-and-co-bdx.html.
Becton Dickinson and Company Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.